Nektar Therapeutics (Nasdaq: NKTR) reported disappointing results from a Phase 2 study of its pain treatment NKTR-181 sending the stock price plummeting $3.31 to close at $10.54.
Disappointing Results For Nektar
September 27, 2013 at 17:33 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||